Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin
Recruiting · NCT05977803 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
MRI with CEST sequence, IVIM and ASL sequence
What this trial is about
The aim of the study is to determine whether the use of the CEST sequence would have diagnostic performance equivalent to the reference method of T2\* infusion with contrast injection in the diagnosis of radionecrosis of lung cancer brain metastases.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients \> 18 years of age
- Histologically proven primary lung cancer
- Histologically proven or not brain metastases
- Irradiated metastases
- Inclusion in a treatment protocol for brain metastases by brain metastasis in toto or stereotactic or gamma-knife radiotherapy
- Morphological increase of one or more lesions of secondary brain metastases on a follow-up MRI
- Patients affiliated to a social security scheme
Exclusion criteria
- Opposition to the study
- Contraindication to MRI
- Refusal of imaging by the patient
- Patient with state medical aid (unless exemption from affiliation)
- Severe cognitive impairment making informed consent impossible
- Patients under guardianship or deprived of liberty
Where it is running
1 location listed.
- Hôpital Bichat-Claude Bernard - Paris, France